Alk-Abello As B Shs New (AKBLF) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Alk-abello A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.959 -- 00:00:05.993 Hello everyone and welcome to this presentation of ALK's Q1 results and 00:00:05.993 -- 00:00:09.883 full year outlook for 2025. Thank you all for joining us. 00:00:09.883 -- 00:00:15.370 Let's turn to slide number two with an introduction to the agenda and the speakers. 00:00:15.370 -- 00:00:19.875 My name is Per Plotnikoff, I am Head of Investor Relations and with me today are CEO 00:00:19.875 -- 00:00:23.379 Peter Halling and CFO Klaus Steensens earlier. 00:00:23.379 -- 00:00:27.023 We will first be sharing a few highlights from the quarter, followed by a closer look 00:00:27.023 -- 00:00:29.646 at the markets, product trends and financials. 00:00:29.646 -- 00:00:33.911 And we will then provide an update on recent progress on our paediatric agenda and on 00:00:33.911 -- 00:00:38.536 the NEFI partnership before we move to the full year outlook. 00:00:38.536 -- 00:00:42.728 As usual, We will end the presentation with a Q&A session. 00:00:42.728 -- 00:00:47.646 And to get started, I'll hand over to Peter and slide number three for the highlights. 00:00:47.646 -- 00:00:49.188 Please go ahead, Peter. 00:00:49.188 -- 00:00:53.095 Thank you, Per, and thank you all for joining today's call. 00:00:53.095 -- 00:00:58.103 As expected, Q1 results were solid. Revenue grew by 12% to 00:00:58.103 -- 00:01:03.232 1.5 billion Danish kroner. Moreover, all sales regions had 00:01:03.232 -- 00:01:07.540 double-digit growth, and we were pleased to see sales in North America bounce back with 00:01:07.540 -- 00:01:12.749 14% growth, as we started to see results from initiatives to get this region 00:01:12.749 -- 00:01:14.956 back on track. 00:01:14.956 -- 00:01:18.722 Across regions, tablets stood out as the main contributor to growth. 00:01:18.722 --...